• *** This stock is shown as delisted in our database. *** If you think this isn't correct then please let us know
Pharmasset, Inc., a clinical-stage pharmaceutical company, focuses on discovering, developing, and commercializing drugs to treat viral infections. Its primary focus is on the development of oral therapeutics for the treatment of hepatitis B virus (HBV), hepatitis C virus (HCV), and human immunodeficiency virus (HIV). The company has three product candidates under development, which include Clevudine, an oral, once-daily pyrimidine nucleoside analog, which is under Phase III clinical trials for the treatment of chronic HBV infection; R7128, a pro-drug of PSI-6130 in Part 3 of a Phase I clinical trial for the treatment of HCV, through a collaboration with F. Hoffmann-LaRoche, Ltd. and Hoffmann-La Roche, Inc.; and Racivir, an oral, once-daily cytidine nucleoside analog, which has completed a Phase II clinical trial for the treatment of HIV. In addition, the company engages in the development of DFC, an oral, once-daily deoxycytidine nucleoside analog, for the treatment of HIV.
Please sign in first
none
none
none
| Insider Name | Type | Last Reported Shares Held | Last Reported Date | Filings in past year |
|---|---|---|---|---|
|
No longer subject to file | 2012-01-12 | 0 | |
|
No longer subject to file | 2012-01-12 | 0 | |
|
LEUTZINGER KURT CHIEF FINANCIAL OFFICER |
|
No longer subject to file | 2012-01-12 | 0 |
|
No longer subject to file | 2012-01-12 | 0 | |
|
BERREY M MICHELLE CHIEF MEDICAL OFFICER |
|
No longer subject to file | 2012-01-12 | 0 |
|
No longer subject to file | 2012-01-12 | 0 | |
|
No longer subject to file | 2012-01-12 | 0 | |
|
ROGERS MICHAEL D. CHIEF DEVELOPMENT OFFICER |
|
No longer subject to file | 2012-01-12 | 0 |
|
OTTO MICHAEL J. CHIEF SCIENTIFIC OFFICER |
|
0 | 2011-11-01 | 0 |
|
PRICE P SCHAEFER PRESIDENT & CEO |
|
0 | 2011-10-11 | 0 |
|
0 | 2010-10-14 | 0 | |
|
30,666 | 2010-03-03 | 0 | |
|
LUBETKIN PAUL EXECUTIVE VP & GENERAL COUNSEL |
|
0 | 2009-10-14 | 0 |
|
No longer subject to file | 2009-09-22 | 0 | |
|
No longer subject to file | 2008-12-31 | 0 | |
|
BAB BIO VENTURES LLP MPM ASSET MANAGEMENT INVESTORS 1999 LLC MPM BIOVENTURES PARALLEL FUND L P MPM BIO VENTURES I LLC |
|
No longer subject to file | 2008-06-19 | 0 |
|
10,655,608 | 2008-06-19 | 0 | |
|
BAB BIO VENTURES LLP MPM ASSET MANAGEMENT INVESTORS 1999 LLC MPM BIOVENTURES PARALLEL FUND L P MPM BIO VENTURES I LLC |
|
2,331,484 | 2008-06-17 | 0 |
|
2,655,463 | 2008-06-13 | 0 | |
|
1,299,634 | 2008-04-02 | 0 | |
|
1,299,634 | 2008-04-02 | 0 | |
|
MPM BIOVENTURES III PARALLEL FUND, LP MPM BIOVENTURES III GMBH & CO. BETEILIGUNGS KG MPM ASSET MANAGEMENT INVESTORS 2004 BVIII LLC |
|
1,325,138 | 2008-02-07 | 0 |
|
1,325,138 | 2008-02-07 | 0 | |
|
1,717 | 2008-02-04 | 0 | |
|
BURRILL & CO (LIFE SCIENCES GP), LLC BURRILL INDIANA LIFE SCIENCES CAPITAL FUND, L.P. |
|
1,872,285 | 2007-05-02 | 0 |
| Reporting Owners | Filing Date | Trans Date | Trans Code | Shares | Share Price | Acquired Disposed |
Shares Owned after | D/I | 10b5 | Perf 1d* | Perf 5d* | Perf 1m* | Max Gain | Max Gain Days | Max Loss | Max Loss Days |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| No current insider transactions | ||||||||||||||||
* -
| Code | Definition |
|---|---|
| A | Grant, award or other acquisition pursuant to Rule 16b-3(d) |
| C | Conversion of derivative security |
| D | Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) |
| E | Expiration of short derivative position |
| F | Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 |
| G | Bona fide gift |
| H | Expiration (or cancellation) of long derivative position with value received |
| I | Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities |
| J | Other acquisition or disposition |
| L | Small acquisition under Rule 16a-6 |
| M | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 |
| O | Exercise of out-of-the-money derivative security |
| P | Open market or private purchase of non-derivative or derivative security |
| S | Open market or private sale of non-derivative or derivative security |
| U | Disposition pursuant to a tender of shares in a change of control transaction |
| W | Acquisition or disposition by will or the laws of descent and distribution |
| X | Exercise of in-the-money or at-the-money derivative security |
| Z | Deposit into or withdrawal from voting trust |
Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers
| Security | Date/Time | Rebate Rate | Fee Rate | Shares Available |
|---|
| Holder | Issuer | Net Short Position | Position Date | Origin |
|---|
